Randomized: 40 mg Paltusotine + Randomized: 80 mg Paltusotine
Phase 2Completed 0 watching 0 views this week⚡ Active
47
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Carcinoid Syndrome
Conditions
Carcinoid Syndrome, Carcinoid, Carcinoid Tumor, Carcinoid Tumor of Ileum, Carcinoid Tumor of Cecum, Carcinoid Syndrome Diarrhea, Carcinoid Intestine Tumor, Carcinoid Tumor of Liver, Carcinoid Tumor of Pancreas
Trial Timeline
Apr 22, 2022 → Feb 24, 2026
NCT ID
NCT05361668About Randomized: 40 mg Paltusotine + Randomized: 80 mg Paltusotine
Randomized: 40 mg Paltusotine + Randomized: 80 mg Paltusotine is a phase 2 stage product being developed by Crinetics Pharmaceuticals for Carcinoid Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT05361668. Target conditions include Carcinoid Syndrome, Carcinoid, Carcinoid Tumor.
Hype Score Breakdown
Clinical
17
Activity
12
Company
5
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05361668 | Phase 2 | Completed |
Competing Products
20 competing products in Carcinoid Syndrome